Zevra Therapeutics, Inc. (ZVRA) Tops Q4 EPS by 53c

Zevra Therapeutics, Inc. (NASDAQ: ZVRA) reported Q4 EPS of $0.60, $0.53 better than the analyst estimate of $0.07. Revenue for the quarter came in at $36.2 million versus the consensus estimate of $31.96 million.

For earnings history and earnings-related data on Zevra Therapeutics, Inc. (ZVRA) click here.

You May Also Be Interested In

• Home Depot beats estimates, reaffirms fiscal 2026 guidance
• Micron Technology (MU) Reiterated at Buy by UBS as Investor Positioning Skews Cautious
• Prenetics IM8 revenue jumps 359% in Q2, raises FY2026 guidance